StoryFunding
CRISPR Therapeutics raises $280 million through registered direct offering led by EcoR1 Capital
CRISPR Therapeutics announced a registered direct offering of $280 million in common shares to institutional investors at $71.50 per share, led by new investor EcoR1 Capital and existing investor SR One. The funds were to advance pipeline programs and manufacturing scale-up.
- New investor EcoR1 Capital and SR One led the offering
- Price of $71.50 per share
- Proceeds for pipeline advancement and manufacturing
- Strategic validation of CRISPR platform by major healthcare investor